The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Loss of Dopamine and Plastic Changes in the Basal Ganglia in PD In PD, the dopaminergic nigrostriatal pathway progressively degenerates. The dopaminergic projections to the sensorimotor striatum are ...

In the past few decades, the indoleamine 2,3 dioxygenase (IDO) subset of the kynurenine (KYN) pathway of tryptophan (TRP) metabolism has been the subject of much research in the area of immune ...

Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder, with an annual incidence of around 16–19 cases per 100,000. [1] As drug therapy in PD is currently ...

First numbering (census) of the Israelites for military purposes and encampment location of each tribe in relation to the Tabernacle About 70 times in the Book of Numbers, we read: The Lord said or ...

Last year, the CMS Innovation Center launched the Quality Pathway strategic initiative to strengthen the focus on quality in alternative payment models. Since it was created, the CMS Innovation ...